Sanofi and Cathay Capital Launch RMB 2 Billion Pharma Innovation Fund in China
The Sanofi Cathy Capital Pharmaceutical Innovation Fund, a joint venture between French pharmaceutical giant Sanofi...
EPA: SAN
Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program
US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...
Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of...
Sanofi’s Qfitlia Approved by FDA for Hemophilia A and B Prophylaxis
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval from the US Food...
Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...
Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
Sanofi (EPA: SAN, NASDAQ: SNY) announced that a market filing for its tolebrutinib as a...
Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China
Opella, the consumer health business of French giant Sanofi (EPA: SAN, NASDAQ: SNY), held a...
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager...
Sanofi’s Sarclisa Wins New Japan Approval for Multiple Myeloma Combination Therapy
Sanofi (EPA: SAN, NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Sanofi’s Dupixent Receives Priority Review from FDA for Bullous Pemphigoid Treatment
Sanofi (EPA: SAN, NASDAQ: SNY) announced that the US Food and Drug Administration (FDA) has...
Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment
The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...
FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial
France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US...
Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma
French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA...
Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies
Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...
Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the...
Sanofi’s Consumer Health Unit Attracts Binding Offers, Potential EUR 15 Billion Deal
French pharmaceutical giant Sanofi S.A. (EPA: SAN; NASDAQ: SNY) has reportedly received multiple binding offers...
Sanofi’s Sarclisa Secures FDA Approval for First-Line Multiple Myeloma Treatment
Sanofi (EPA: SAN; NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA)...
Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant...
Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives
Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...